SCHEMBL4810156

SCHEMBL4810156

CC(C)COc1ccc(C2OCC2(C)C)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.38
▸ HPGD P15428 4/20 0.38
▸ POLB P06746 4/20 0.38
▸ ALDH1A1 P00352 3/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ TSHR P16473 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ ACACB O00763 5/20 0.37
▸ BRD4 O60885 1/20 0.37
▸ CREBBP Q92793 1/20 0.37
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ XBP1 P17861 1/20 0.36
▸ USP2 O75604 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12619934 0.87 USP1 (0.33) ALDH1A1KDM4EUSP1MEN1KMT2A
SCHEMBL13651771 0.87 TDP1 (0.49) MAPTALDH1A1CYP2C9TSHRNPSR1
SCHEMBL13651823 0.84 MAPT (0.39) MAPTALDH1A1NPC1LMNAUSP1
SCHEMBL13183274 0.83 NQO1 (0.47) MAPTALDH1A1KDM4ETSHRLMNA
SCHEMBL14590563 0.83 USP1 (0.32) USP1
SCHEMBL14193796 0.82 HPGD (0.37) MAPTHPGDPOLBALDH1A1KDM4E
SCHEMBL13651821 0.80 ALDH1A1 (0.36) MAPTALDH1A1KDM4ETSHRNPC1
SCHEMBL10329404 0.80 OPRM1 (0.43) —
SCHEMBL13651779 0.80 ALDH1A1 (0.49) MAPTALDH1A1CYP2C19TSHRNPC1
SCHEMBL4806456 0.80 NPC1 (0.48) MAPTALDH1A1NPC1LMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090252895-A1 Actinic ray curable composition, actinic ray curable ink and image formation method employing the ink KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2009-10-08 — — US disclosed
US-20090252895-A1 Actinic ray curable composition, actinic ray curable ink and image formation method employing the ink KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2009-10-08 — — US disclosed
US-20080107821-A1 Polymerizable Actinic Radiation Curable Composition, Polymerization Method, Actinic Radiation Curable Ink and Image Formation Method, and Ink Jet Recording Apparatus and Epoxy Compound KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2008-05-08 — — US disclosed
US-20080107821-A1 Polymerizable Actinic Radiation Curable Composition, Polymerization Method, Actinic Radiation Curable Ink and Image Formation Method, and Ink Jet Recording Apparatus and Epoxy Compound KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2008-05-08 — — US disclosed
US-7360883-B2 Active ray curable ink, image forming method and ink-jet recording apparatus KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2008-04-22 — — US disclosed
US-7360883-B2 Active ray curable ink, image forming method and ink-jet recording apparatus KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2008-04-22 — — US disclosed
US-20070219292-A1 INK SET FOR INK-JET RECORDING, POLYMERIZATION METHOD AND IMAGE FORMING METHOD KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2007-09-20 — — US disclosed
US-20070219292-A1 INK SET FOR INK-JET RECORDING, POLYMERIZATION METHOD AND IMAGE FORMING METHOD KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2007-09-20 — — US disclosed
EP-1829936-A1 ACTIVE RAY-CURABLE COMPOSITION, ACTIVE RAY-CURABLE INK AND IMAGE-FORMING METHOD Konica Minolta Medical & Graphic, Inc. (JP) 2007-09-05 — — EP disclosed
US-20050190252-A1 Active ray curable ink, image forming method and ink-jet recording apparatus KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2005-09-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080107821-A1 Polymerizable Actinic Radiation Curable Composition, Polymerization Method, Actinic Radiation Curable Ink and Image Formation Method, and Ink Jet Recording Apparatus and Epoxy Compound CBR3, CBR1, CNR1 MAPT 3075/4885HPGD 3102/4885POLB 1287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback